TABLE 6.
Treatment of an influenza A/Duck/MN/1525/81 (H5N1) amantadine-resistant virus infection in mice with amantadine and oseltamivir used alone or in combination (second experiment)a
| Compound 1 (mg/kg/day) | Compound 2 (mg/kg/day) | No. of survivors/ total no.c | MDD ± SDb |
|---|---|---|---|
| Amantadine (100) | 0/10 | 6.9 ± 1.1 | |
| Oseltamivir (75) | 5/10** | 7.6 ± 2.3 | |
| Oseltamivir (25) | 8/10*** | 6.5 ± 0.7 | |
| Amantadine (100) | Oseltamivir (75) | 6/10*** | 7.5 ± 1.3 |
| Amantadine (100) | Oseltamivir (25) | 9/10*** | 6.0 |
| Placebo | 0/20 | 7.0 ± 1.1 |
a
Oral treatments were given twice a day for 5 days starting 4 h prior to virus exposure.
b
MDD, Mean day of death of mice that died prior to day 21.
c
**, P < 0.01; ***, P < 0.001, compared to placebo.